<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03486665</url>
  </required_header>
  <id_info>
    <org_study_id>BIT-001</org_study_id>
    <nct_id>NCT03486665</nct_id>
  </id_info>
  <brief_title>Characterization of White Blood Cells Sub-populations From Multiple Sclerosis Patients.</brief_title>
  <official_title>Characterization and Quantitative Analysis of White Blood Cells in the Blood and Cerebrospinal Fluid of MS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioimmunate</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioimmunate</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple sclerosis (MS) is a chronic progressive neurological autoimmune disease, that
      gradually affects patient's quality of life. There are about 2.5 millions patients world
      wide, with an increasing cost Burdon. Up to date, it remains unclear who are the exact cells
      to initiate the disease. During the disease, the repertoire of cells expands and undergoes
      changes. The purpose of this study is to characterize those changes.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of disease related white blood cells from blood and/ or CSF</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Diagnosed with Multiple Sclerosis</arm_group_label>
    <description>Patients previously diagnosed with Multiple Sclerosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Newly Diagnosed with Multiple Sclerosis</arm_group_label>
    <description>Patients diagnosed for the first time with Multiple Sclerosis and hospitalized</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <description>Health volunteers who do not have an autoimmune diseases, including Multiple Sclerosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Sampling</intervention_name>
    <description>Blood samples will be taken from all patients and healthy volunteers.</description>
    <arm_group_label>Diagnosed with Multiple Sclerosis</arm_group_label>
    <arm_group_label>Newly Diagnosed with Multiple Sclerosis</arm_group_label>
    <arm_group_label>Healthy Volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CSF Sampling</intervention_name>
    <description>CSF sample will be taken from hospitalized newly diagnosed patients only.</description>
    <arm_group_label>Newly Diagnosed with Multiple Sclerosis</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood CSF
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        18 to 70 years old patients with MS defined according to the revised diagnostic criteria of
        MacDonald and are followed by the neurology or physical medicine and rehabilitation center
        or healthy volunteers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with diagnosis of MS according to the revised criteria of McDonald or healthy
             volunteers

          -  Ability to provide written informed consent.

        Exclusion Criteria:

        - Active malignant disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sigalit Carmel, MD, MSc</last_name>
    <phone>+97225649302</phone>
    <email>sigalit@bioimmunate.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ariel Ginzberg, PHD</last_name>
      <phone>+972 2 6776939</phone>
    </contact>
    <investigator>
      <last_name>Dimitrios Karussis, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>April 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2018</study_first_posted>
  <last_update_submitted>April 1, 2018</last_update_submitted>
  <last_update_submitted_qc>April 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

